Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.53 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17207658 | 0.84 | GPR119 (0.43) | DDB1CRBNCHRNA7ACHEGPR119 | |
| SCHEMBL18791108 | 0.80 | CKS1B (0.48) | DDB1CRBNGPR119CKS1BSKP1 | |
| SCHEMBL3274585 | 0.78 | ACHE (0.66) | DDB1CRBNCHRNA7ACHEGPR119 | |
| SCHEMBL25232441 | 0.76 | ACHE (0.58) | DDB1CRBNCHRNA7ACHEGPR119 | |
| SCHEMBL15286547 | 0.76 | ACHE (0.62) | DDB1CRBNCHRNA7ACHEGPR119 | |
| SCHEMBL3651086 | 0.76 | ACHE (0.57) | DDB1CRBNCHRNA7ACHEGPR119 | |
| SCHEMBL3268895 | 0.75 | ACHE (0.57) | DDB1CRBNCHRNA7ACHEGPR119 | |
| SCHEMBL1433109 | 0.75 | ACHE (0.61) | DDB1CRBNCHRNA7ACHEGPR119 | |
| SCHEMBL30166226 | 0.75 | ACHE (0.61) | DDB1CRBNCHRNA7ACHEGPR119 | |
| SCHEMBL19015403 | 0.75 | ACHE (0.61) | DDB1CRBNCHRNA7ACHEGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044115-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
| US-20170044115-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044115-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | NR3C2, REN, CYP21A2 | DDB1 3009/4885CRBN 1402/4885CHRNA7 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.